inclisiran 的有效性,益处和安全性
1Unidad de Lípidos y Arteriosclerosis, Departamento de Medicina Interna, Hospital Universitario Reina Sofía, Universidad de Córdoba, IMIBIC, CIBEROBN, Córdoba, España.
概括
通过向PCSK-9,Inclisiran显著降低LDL胆固醇,为高胆固醇血症提供方便的每年两次剂量. 这种新的治疗方法可以改善坚持并有效降低心血管风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 高胆固醇血症是动脉样硬化心血管疾病 (ASCVD) 的主要驱动因素,是西班牙的主要死亡原因.
- 降低LDL胆固醇 (LDL-C) 对于降低ASCVD风险和不良心血管事件至关重要.
- 蛋白转化酶亚素/素9型 (PCSK-9) 向疗法为高脂血症管理提供了一种新的方法.
研究的目的:
- 审查目前关于Inclisiran在高胆固醇血症中的疗效,耐受性和安全性的科学数据.
- 讨论Inclisiran的作用机制及其与现有的降脂疗法相比的优势.
- 为了突出Inclisiran在实现LDL-C目标方面不经常使用的剂量方案的重要性.
主要方法:
- 审查现有的科学文献和临床试验数据关于Inclisiran.
- 分析Inclisiran对LDL-C,PCSK-9和其他有机脂蛋白的影响.
- 与安慰剂和其他治疗方法相比,评估Inclisiran的安全性和耐受性.
主要成果:
- 在LDL-C水平上,Inclisiran表现出显著而持续的降低.
- 该疗法导致PCSK-9和异位性脂蛋白水平显著下降.
- 英克利西兰表现出有利的副作用,与安慰剂相当,并提供方便的每年两次的剂量计划.
结论:
- 英克利西兰是高胆固醇血症的有效和耐受治疗方法,可长期降低LDL-C.
- 不常见的剂量方案提高了治疗的坚持,促进了LDL-C目标的实现.
- 目前正在进行的试验将进一步阐明Inclisiran在高风险患者的心血管益处.
更多相关视频
相关概念视频
01:22Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
01:13Therapeutic Index
4.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.1K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
468
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
468
01:11Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115